Duncan B McLaren
Duncan B McLaren
Professor and Consultant Clinical Oncologist , University of Edinburgh
Verified email at igmm.ed.ac.uk - Homepage
Title
Cited by
Cited by
Year
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
12742016
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)
ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ...
European urology 67 (6), 1028-1038, 2015
3402015
Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
DB McLaren, M McKenzie, G Duncan, T Pickles
Cancer: Interdisciplinary International Journal of the American Cancer …, 1998
1411998
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
Lancet 387 (10024), 1163-77, 2016
1372016
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ...
The Lancet Oncology 21 (1), 162-174, 2020
1342020
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
1322018
The relevance of a hypoxic tumour microenvironment in prostate cancer
GD Stewart, JA Ross, DB McLaren, CC Parker, FK Habib, ACP Riddick
BJU international 105 (1), 8-13, 2010
1002010
Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly
DB McLaren, D Morrey, MD Mason
Radiotherapy and oncology 43 (2), 171-174, 1997
781997
Clinical and patient‐reported outcomes of SPARE–a randomised feasibility study of selective bladder preservation versus radical cystectomy
RA Huddart, A Birtle, L Maynard, M Beresford, J Blazeby, J Donovan, ...
BJU international 120 (5), 639-650, 2017
632017
Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy
DJ Storey, DB McLaren, MA Atkinson, I Butcher, LC Frew, JF Smyth, ...
Annals of oncology 23 (6), 1542-1549, 2012
622012
Testicular sex cord–stromal tumours: the Edinburgh experience 1988–2002, and a review of the literature
DS Conkey, GCW Howard, KM Grigor, DB McLaren, GR Kerr
Clinical Oncology 17 (5), 322-327, 2005
602005
Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the …
ND James, SJ Pirrie, AM Pope, D Barton, L Andronis, I Goranitis, S Collins, ...
JAMA oncology 2 (4), 493-499, 2016
502016
Clinically relevant fatigue in recurrence-free prostate cancer survivors
DJ Storey, DB McLaren, MA Atkinson, I Butcher, S Liggatt, R O’Dea, ...
Annals of oncology 23 (1), 65-72, 2012
412012
DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions
GD Stewart, J Nanda, E Katz, KJ Bowman, JG Christie, DJG Brown, ...
Biochemical pharmacology 81 (2), 203-210, 2011
412011
Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy
GS Higgins, DB McLaren, GR Kerr, T Elliott, GCW Howard
International Journal of Radiation Oncology* Biology* Physics 65 (4), 982-989, 2006
402006
Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique
S Borgaonkar, A Jain, P Bollina, DB McLaren, D Tulloch, GR Kerr, ...
Clinical Oncology 14 (2), 141-147, 2002
392002
Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 …
ND James, S Pirrie, D Barton, JE Brown, L Billingham, SI Collins, ...
Journal of Clinical Oncology 31 (18_suppl), LBA5000-LBA5000, 2013
382013
Image-guided radiotherapy of bladder cancer: bladder volume variation and its relation to margins
LP Muren, AT Redpath, H Lord, D McLaren
Radiotherapy and Oncology 84 (3), 307-313, 2007
342007
A core outcome set for localised prostate cancer effectiveness trials
S MacLennan, PR Williamson, H Bekema, M Campbell, C Ramsay, ...
Wiley, 2017
332017
Cyborgs in the everyday: Masculinity and biosensing prostate cancer
G Haddow, E King, I Kunkler, D McLaren
Science as Culture 24 (4), 484-506, 2015
292015
The system can't perform the operation now. Try again later.
Articles 1–20